Another SGLT2 inhibitor therapy has been recommended for listing on the PBS.

At its March 2018 meeting the Pharmaceutical Benefits Advisory Committee recommended an Authority Required (Streamlined) listing for ertugliflozin for dual oral therapy with metformin or a sulfonylurea.

The PBAC said it considered the evidence presented in the application from Merck Sharp & Dohme supported a claim of non-inferior efficacy and safety for ertugliflozin compared to dapagliflozin or empagliflozin.

The listing covers tablets containing ertugliflozin (Steglatro) and fixe dose combinations of ertugliflozin with metformin (Segluromet).

At the same meeting an unrestricted PBS listing was recommended for insulin degludec with insulin aspart (IDegAsp) for treatment of adult patients with diabetes mellitus where insulin treatment is necessary.

In response to an application for listing of Ryzodeg FlexTouch and Penfill products by Novo Nordisk, the PBAC said biphasic insulin aspart (BIAsp 30) could be considered the appropriate comparator for IDegAsp in type 1 and type 2 diabetes mellitus populations.